Business
Vor Names Oncology Drug Development Expert as CMO
Vor Names Oncology Drug Development Expert as CMO.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n RNS Number : 8850S\n PureTech Health PLC\n 13 July 2020\n \n \n \n \n 14 July 2020\n \n \n PureTech Health plc\n \n \n \n \n \n \n PureTech Founded Entity \n \n \n Vor Biopharma Appoints Dr Christopher Slapak as Chief Medical Officer\n \n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (LSE: PRTC) (\"PureTech\"\n \n or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vor Biopharma, today announced it has appointed Christopher Slapak, MD, as chief medical officer. Dr Slapak has more than 20 years of leadership experience in oncology drug development and previously led global clinical development for all early-stage oncology compounds for Eli Lilly and Company. \n \n \n \n \n \n \n The full text of the announcement from Vor is as follows:\n \n \n \n \n \n Vor Biopharma Appoints Dr Christopher Slapak as Chief Medical Officer\n \n \n \n \n \n CAMBRIDGE, Mass., - July 14, 2020 - \n \n \n Vor Biopharma\n \n \n , an oncology company pioneering engineered haematopoietic stem cells (eHSCs) for the treatment of cancer, today announced it has appointed Christopher Slapak, MD, as chief medical officer. Dr Slapak has more than 20 years of leadership experience in oncology drug development and previously led global clinical development for all early-stage oncology compounds for Eli Lilly and Company. \n \n \n \n \n \n \"As Vor rapidly advances to become a clinical-stage company, it is wonderful for Christopher to commit to this full-time role leading the development of our oncology therapeutics,\" said Robert Ang, MBBS, MBA, Vor's president and chief executive officer. \n \n \n \n \n \n Dr Slapak has served as Vor's interim chief medical officer since July 2019 as part of his work as an independent consultant advising on scientific and medical aspects of oncology drug development. For more than 20 years, he held leadership roles at Eli Lilly and Company, including positions as distinguished Lilly scholar and vice president, early phase research. He oversaw the global clinical development of all early-stage oncology compounds for Lilly and ImClone (which was acquired by Lilly in 2008), including the successful earl...